HALUK YUZUGULLU

Dikutip oleh

	Semua	Sejak 2020
Kutipan	3262	1692
indeks-h	12	11
indeks-i10	12	11

420

210

105

315

201020112012201320142015201620172018201920202021202220232024202519 34 41 46 60 116 230 273 322 382 379 404 354 255 273 27

Akses publik

Lihat semua

8 artikel

0 artikel

tersedia

tidak tersedia

Berdasarkan pada mandat pendanaan

Pengarang bersama

Serif SenturkProfessor at Dokuz Eylul University & Group Leader at Izmir Biomedicine and Genome CenterEmail yang diverifikasi di ibg.edu.tr
Ozge gursoy YuzugulluDana Farber Cancer Institute, Harvard Medical SchoolEmail yang diverifikasi di dfci.harvard.edu
Nuri OzturkProfessor @ Gebze Technical UniversityEmail yang diverifikasi di gtu.edu.tr
Adam C PalmerAssistant Professor, UNC-Chapel HillEmail yang diverifikasi di unc.edu
Wei LiAssociate Professor, Children's National Hospital, George Washington UniversityEmail yang diverifikasi di childrensnational.org
Xiaole Shirley LiuCEO, GV20 TherapeuticsEmail yang diverifikasi di ds.dfci.harvard.edu
Richard YoungProfessor of Biology, MITEmail yang diverifikasi di wi.mit.edu
Daniel G. StoverOhio State University Comprehensive Cancer CenterEmail yang diverifikasi di osumc.edu
Ayça Arslan ErgülUNAM, Bilkent UniversityEmail yang diverifikasi di bilkent.edu.tr
Kira GritsmanAlbert Einstein College of MedicineEmail yang diverifikasi di einsteinmed.edu
Cigdem Ozen, Ph.D.TU Dresden, Bioinformatics, Center for Molecular and Cellular Bioengineering (CMCB)Email yang diverifikasi di tu-dresden.de
Hilal Ozdag PhDAnkara University Biotechnology InstituteEmail yang diverifikasi di ankara.edu.tr
Rengul Cetin AtalayUniversity of ChicagoEmail yang diverifikasi di uchicago.edu
nejat akarTOBB-ETU Medical School Pediatrics DepartmentEmail yang diverifikasi di etu.edu.tr
Gokhan YildizKaradeniz Technical University School of Medicine Department of Medical BiologyEmail yang diverifikasi di ktu.edu.tr
biter bilenPostdoctoral fellowEmail yang diverifikasi di stanford.edu
Bala Gur DedeogluAnkara University Biotechnology InstituteEmail yang diverifikasi di ankara.edu.tr
Isik G. YulugAssociate Professor of Molecular Biology and Genetics, Bilkent UniversityEmail yang diverifikasi di fen.bilkent.edu.tr
Yongmin ChoiUniversity of Southern CaliforniaEmail yang diverifikasi di usc.edu

Ikuti

HALUK YUZUGULLU

Astrazeneca Pharmaceuticals

Email yang diverifikasi di astrazeneca.com

cancer stem cells breast cancer PDX leukemia liver cancer colorectal carcinoma


Judul Urutkan menurut kutipan Urutkan menurut tahun Urutkan menurut judul	Dikutip oleh Dikutip oleh	Tahun
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting HYJJZ Lauren M. Thorpe Nature Reviews Cancer 15 (1), 7–24, 2014	1466*	2014
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors JJZ Shom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon ... Cancer Cell 29 (3), p255–269, 2016	467	2016
CDK7-dependent transcriptional addiction in triple-negative breast cancer Y Wang, T Zhang, N Kwiatkowski, BJ Abraham, TI Lee, S Xie, H Yuzugullu, ... Cell 163 (1), 174-186, 2015	456	2015
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells H Yuzugullu, K Benhaj, N Ozturk, S Senturk, E Celik, A Toylu, N Tasdemir, ... Molecular cancer 8, 1-20, 2009	311	2009
Senescence and immortality in hepatocellular carcinoma M Ozturk, A Arslan-Ergul, S Bagislar, S Senturk, H Yuzugullu Cancer letters 286 (1), 103-113, 2009	128	2009
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. SP Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE ... Cancer Cell 31 (4), 576–590, 2017	102	2017
Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation O Gursoy‐Yuzugullu, H Yuzugullu, M Yilmaz, M Ozturk Liver International 31 (4), 561-571, 2011	95	2011
Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu, ... PloS one 8 (5), e64016, 2013	70	2013
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α K Gritsman, H Yuzugullu, T Von, H Yan, L Clayton, C Fritsch, SM Maira, ... The Journal of clinical investigation 124 (4), 1794-1809, 2014	64	2014
A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis H Yuzugullu, L Baitsch, T Von, A Steiner, H Tong, J Ni, LK Clayton, ... Nature communications 6 (1), 8501, 2015	50	2015
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity M Mumcuoglu, S Bagislar, H Yuzugullu, H Alotaibi, S Senturk, ... PloS one 5 (6), e11288, 2010	29	2010
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways H Yuzugullu, T Von, LM Thorpe, SR Walker, TM Roberts, DA Frank, ... Cell discovery 2 (1), 1-13, 2016	21	2016
Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma U Ekin, H Yuzugullu, C Ozen, P Korhan, E Bagirsakci, F Yilmaz, ... Journal of Gastrointestinal Cancer, 1-14, 2021	3	2021
First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi … V Samnotra, V Moroz, L Shtessel, M Kuchimanchi, P Hanafin, ... Journal of Clinical Oncology 42 (16_suppl), TPS3174-TPS3174, 2024		2024
Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly (ADP-ribose) polymerase (PARP … V Samnotra, V Moroz, L Shtessel, M Kuchimanchi, P Hanafin, ... Cancer Research 84 (7_Supplement), CT169-CT169, 2024		2024
Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer S Ghassemifar, Y Hashambhoy-Ramsay, H Yuzugullu, T Utermark, ... Cancer Research 79 (13_Supplement), 700-700, 2019		2019
Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist D Tamara, S Ghassemifar, Y Hashambhoy-ramsay, DHC MARCANTONIO, ... US Patent App. 16/305,289, 2019		2019
INVESTIGATION OF CAUSATIVE AGENTS IN COMMUNITY-ACQUIRED ATYPICAL PNEUMONIA CASES E ÇALIŞKAN, Ş ÖKSÜZ, C ÖZTÜRK, I Sahin, O Kilincel, N Akar, ... FRESENIUS ENVIRONMENTAL BULLETIN 28 (5), 2019		2019
MM-161, a first-in-class pan-FGFR antibody T Dake, G Finn, M Geddie, N Kohli, M Razlog, L Xu, V Paragas, ... Cancer Research 77 (13_Supplement), 22-22, 2017		2017
Targeted Therapy for Hepatocellular Carcinoma: What`s New? H Yuzugullu, O Gursoy-Yuzugullu Liver Res Open J 1 (1), e1-e3, 2015		2015

Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.

Artikel 1–20

Kutipan per tahun

Kutipan duplikat

Kutipan yang digabung

Tambahkan pengarang bersamaPengarang bersama

Ikuti

Dikutip oleh

Pengarang bersama